Azor(TM) Reduces Blood Pressure in Difficult to Treat Special P...(ions such as people with diabetes. H...),Health

Hypertension, also known as high blood pressure, affects approximately 72 million people in the United States and approximately one billion worldwide.(5)(6) Called the "silent killer" because it often has no specific symptoms, hypertension increases the risk of cardiovascular and related diseases such as stroke, heart attack, heart failure and kidney disease.(7) Of those diagnosed with high blood pressure, 64.9 percent do not have the condition under control.(8)

ABOUT THE ANALYSES

RACE/ETHNICITY:

Blood pressure control in patients with hypertension remains unsatisfactorily low in the US, particularly in Black and Hispanic/Latino populations, with fewer than 30% of patients in these minority groups treated to goal BP.(9)(10) Guidelines acknowledge that combination therapy will be required for the majority of patients to attain BP goals, and recommend that combination therapy utilizing agents from complimentary drug classes should be considered when BP is difficult to control or there is high cardiovascular risk, such as in minority patient populations.(11)(12)(13)

Of the 1,940 patients who entered the eight week pivotal study, 1,459 were non-Black and 481 were Black. Further, ethnicity was asked separately from race: 245 patients were Hispanic/Latino. All subgroups were matched for baseline BP of 164/102 mm Hg. AZOR 10/40 mg demonstrated a 29/16 mm Hg mean reduction in the Black cohort vs. 31/20 mm Hg in non-blacks. Further, in the Hispanic/Latino study patient population, AZOR 10/40 mg demonstrated a mean reduction of 29/21 mm Hg compared to 30/19 mm Hg in non-Hispanic/non-Latino.

BMI:

A higher body mass index (BMI) often makes it more difficult for patients with hypertension to achieve target BP.(14) The analysis of data from the pivotal study demonstrated the ability of AZOR to produce substantial reductions in BP compared to the monotherapy components, regardless of BMI
'/>"/>